IsolateFibromyalgia test to ascertain Fibromyalgia by IQuity

IQuity has declared the release of IsolateFibromyalgia which is a pioneering blood test that utilizes RNA analysis to aid health care providers accurately and quickly ascertain fibromyalgia syndrome.

IsolateFibromyalgia uses a simple blood draw to detect, with 94 percent accuracy, if a patient’s gene expression pattern is consistent with fibromyalgia syndrome. The extensive disease controls used in the creation of IsolateFibromyalgia make the test highly accurate in differentiating fibromyalgia from conditions that it mimics or that could be misdiagnosed as fibromyalgia.

Dr. Chase Spurlock, CEO of Equity said “Unlike DNA, which can predict the risk of certain diseases, RNA shows what’s taking place right now in a patient’s cells. That information can speed up the pace of diagnosis for physicians, leading to faster, more effective treatment for patients.”

Fibromyalgia is a central nervous system disorder that afflicts between 6 and 12 million Americans, according to the American Chronic Pain Association. Its symptoms vary among patients, but many struggle with intense pain throughout the body, as well as fatigue, depression and difficulty concentrating.